🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: BGF MDI (PT010)

Found 13 matching trials

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

PHASE3

This is a variable length study to evaluate the efficacy and safety of bude...

Status

Completed

Location

Research Site

Start Date

2021-03-01

Trial ID

NCT04609904

Treatments Being Tested

BGF MDI 320/28.8/9.6 μg BGF MDI 320/14.4/9.6 μg BFF MDI 320/9.6 μg BFF pMDI 320/9 μg

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

PHASE3

This is a randomized, double-blind, multi-center, parallel-group study to a...

Status

Completed

Location

Research Site

Start Date

2015-06-30

Trial ID

NCT02465567

Treatments Being Tested

BGF MDI 320/14.4/9.6 μg GFF MDI 14.4/9.6 μg BGF MDI 160/14.4/9.6 μg BFF MDI 320/9.6 μg

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

PHASE3

A Randomized, Double-Blind, Parallel Group, 28-Week Chronic Dosing, Multi-C...

Status

Completed

Location

Research Site

Start Date

2016-08-09

Trial ID

NCT03262012

Treatments Being Tested

BGF MDI (PT010)GFF MDI (PT003)BFF MDI (PT009)Symbicort® Turbohaler® Inhalation Powder

A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010

PHASE1

Randomized, Open-label, Single-dose, Single-center, Crossover Study in Heal...

Status

Completed

Location

Pearl Investigative Site

Start Date

2017-10-17

Trial ID

NCT03311373

Treatments Being Tested

Regimen A Regimen B Regimen C Regimen D

Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects

PHASE1

A study to assess the pharmacokinetics and safety of two doses of PT010 and...

Status

Completed

Location

Research Site

Start Date

2017-04-17

Trial ID

NCT03075267

Treatments Being Tested

PT010 (BGF MDI) 320/14.4/9.6 µg PT010 (BGF MDI) 160/14.4/9.6 µg PT003 (GFF MDI) 14.4/9.6 µg

A Scintigraphy Study of PT010 in COPD Patients

PHASE1

This study is a single treatment period, single dose gamma scintigraphy stu...

Status

Completed

Location

Research Site

Start Date

2019-04-04

Trial ID

NCT03906045

Treatments Being Tested

BGF-MDI

Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers

PHASE1

This is a Phase I, Randomized, Double-Blind Within Device, Single-Dose, Fou...

Status

Completed

Location

Pearl Therapeutics Study Site

Start Date

2013-11

Trial ID

NCT01980615

Treatments Being Tested

Inhaled BGF (PT010) Dose 1 Inhaled BGF (PT010) Dose 2 Inhaled BGF (PT010) Dose 3 Inhaled GFF (PT003)Inhaled Symbicort Dose 1 Inhaled Symbicort Dose 2

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)

PHASE3

Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared...

Status

Completed

Location

Research Site

Start Date

2015-08-10

Trial ID

NCT02497001

Treatments Being Tested

BGF MDI 320/14.4/9.6 μg GFF MDI (PT003) 14.4/9.6 μg BFF MDI (PT009) 320/9.6 μg Symbicort® Turbuhaler® (TBH) Inhalation Powder

To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

PHASE3

This is a 12-week chronic-dosing study to assess the efficacy and safety of...

Status

Withdrawn

Location

Multiple Locations

Start Date

2018-04-16

Trial ID

NCT03081247

Treatments Being Tested

BGF 320/14.4/9.6 µg MDI BFF 320/9.6 µg

A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate

PHASE1

This study is a 2 treatment period, single dose crossover, gamma scintigrap...

Status

Completed

Location

Research Site

Start Date

2018-09-04

Trial ID

NCT03740373

Treatments Being Tested

BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold

Previous Next